Presynaptic dopamine compartmentalization defects initiate auxilin-mediated parkinsonism
Objective: To evaluate the pathogenic mechanisms for auxilin-mediated Parkinson’s disease (PD). Background: Auxilin participates in uncoating of clathrin-coated vesicles (CCVs), thereby facilitating synaptic vesicle (SV)…Longitudinal combined 11C UCB J and 18F FE PE2I PET imaging of presynaptic terminal loss in early Parkinson’s disease.
Objective: To longitudinally assess presynaptic terminal loss in vivo over a 2-year period in people with early Parkinson’s disease (PD). Background: Imaging tools that allow…Widespread loss of presynaptic terminal marker SV2A in early Huntington’s disease.
Objective: To assess synaptic damage in early stages of Huntington’s disease (HD) in vivo. Background: Synaptic damage has long been suspected to play a major…Auxilin knockout mice: a model for Parkinsonism with dopamine dysregulation and synucleinopathy
Objective: To evaluate the role of auxilin in the pathogenesis of Parkinson’s disease (PD). Background: Auxilin or DNAJC6, a brain-specific co-chaperone plays central role in…Movement Disorders After Bariatric Surgeries – Case Series
Objective: Our objective is to report 6 cases series of MD after Bariatric surgeries (BS) and one case after hiatal surgery, with BS behavior. Background:…Premotor compensatory mechanisms in Parkinson’s disease with LRRK2-R1441H mutation
Objective: To investigate the time course of modifications in dopaminergic terminals during the premotor phase in LRRK2 genetically determined Parkinson’s disease (PD). Background: Increased dopamine…DNAJC13 in Parkinson’s disease; characterization of the p.N855S knock-in mouse model
Objective: To study the effects of DNAJC13 p.Asn855Ser mutant gene dysfunction in a physiological context, and to help define molecular mechanisms for disease, using a…Clinical and DAT Imaging Characteristics of Participants with Scans without Evidence of Dopaminergic Deficit (SWEDDs): PPMI Cohort 2 year follow-up
Objective: To examine the clinical and biological characteristics of participants with scans without evidence of dopaminergic deficit (SWEDD) during a two-year follow-up. Background: Study participants…Comparison of PDE10A and DAT expression as markers of disease burden in early Parkinson’s disease
Objective: We aimed to compare loss of PDE10A and DAT expression in patients with Parkinson’s disease. Background: Recent work has shown loss of PDE10A expression…Age-related failure in compensatory mechanisms and its relation to the Parkinson phenotype: evidence from a SPECT study in early and late-onset PD
Objective: To investigate if a less prominent dopaminergic dysfunction on 123I-ioflupane SPECT imaging (DaTSCAN) despite a more severe motor phenotype in Late Onset Parkinson’s Disease…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.